OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

LONDON & NEW YORK & NORTH AUGUSTA, S.C.--(BUSINESS WIRE)-- #DryEye--OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans a Q4 2022 IND filing for OK-101 to treat dry eye disease (DED), with AmbioPharm playing a key role in peptide manufacturing and development. OK-101 is a lipid-peptide analog developed using a novel membrane-anchored peptide (MAP) technology. It con